Exploring the potential of tamoxifen-based copper(<scp>ii</scp>) dichloride in breast cancer therapy-Reference-Cited by-同舟云学术

Exploring the potential of tamoxifen-based copper(ii) dichloride in breast cancer therapy

Published:2023 Issue:12 Volume:14 Page:2574-2582
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Kazimir Aleksandr¹^ORCID,Schwarze Benedikt²^ORCID,Lönnecke Peter¹^ORCID,Jelača Sanja³^ORCID,Mijatović Sanja³^ORCID,Maksimović-Ivanić Danijela³,Hey-Hawkins Evamarie¹^ORCID

Affiliation:

1. Institute of Inorganic Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, Leipzig, Germany

2. Institute of Medical Physics and Biophysics, Faculty of Medicine, Leipzig University, Germany

3. Department of Immunology, Institute for Biological Research “Siniša Stanković”, National Institute of the Republic of Serbia, University of Belgrade, Bulevar despota Stefana 142, 11060 Belgrade, Serbia

Abstract

This study explores a copper-tamoxifen hybrid drug as a promising alternative to platinum complexes in breast cancer therapy, offering a new mechanism of action.

Funder

Deutscher Akademischer Austauschdienst

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MD/D3MD00344B

Reference50 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Mechanisms of Endocrine Resistance in Breast Cancer

3. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

4. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients

5. D. H.Anderson , in Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance , ed. A. Freywald and F. J. Vizeacoumar , Academic Press , 2021 , vol. 12 , pp. 1–22